gdc
PSSGuide_2021

Drugs for Solid Tumors with Gene Alterations

Find financial assistance programs available for drugs for solid tumors with gene alterations.

Jemperli (dostarlimab-gxly) Injection

Drug company: GlaxoSmithKline
844-447-5662

Jemperli is a PD-1 inhibitor used for the treatment of adults with solid tumors associated with mismatch repair-deficient (dMMR), as determined by an FDA-approved test, that have progressed during or after treatment and who have no satisfactory alternative treatment options.

GSK Oncology offers 2 financial assistance programs for patients using Jemperli:

Together with GSK Oncology Commercial Co-pay Program

Eligible patients who have private insurance can pay as little as $0 for Jemperli through this program, with a maximum annual benefit of $26,000.

GSK Patient Assistance Program

Eligible patients who are uninsured or underinsured may receive Jemperli for free through this program. Qualified patients must have a maximum monthly household gross income of $5,366.67 for individuals; $7,258.33 for a family of 2; $9,150.00 for a family of 3; $11,041.67 for a family of 4; and $1,891.67 for each additional person.

Keytruda (pembrolizumab)

Drug company: Merck
855-257-3932

Keytruda is a PD-1 inhibitor used for the treatment of adults and children with unresectable or metastatic, microsatellite instability-high (MSI-H) or mismatch repair-deficient (dMMR) solid tumors that have progressed after previous treatment and who have no satisfactory alternative treatment. Keytruda is also used for the treatment of adults and children with unresectable or metastatic solid tumors and high tumor mutational burden, as determined by an FDA-approved test, that have progressed after previous treatment and who have no satisfactory alternative treatment.

Merck offers 2 financial assistance programs for patients who have been prescribed Keytruda:

Merck Co-pay Assistance Program

Privately insured patients will pay the first $25 of their copay per Keytruda infusion. The maximum benefit per calendar year is $25,000 for patients with an income level up to 700% of the federal poverty level, and $10,000 for patients with an income above 700% of the federal poverty level.

Merck Patient Assistance Program

Patients without insurance or prescription coverage may be eligible to receive Keytruda at no cost. Eligible patients must have a household income of $64,400 or less for individuals, $87,100 or less for a couple, or $132,500 or less for a family of 4. Patients with insurance, including Medicare Part D, who still have trouble paying for their medicines may request that an exception be made, provided their household income is not above a set limit.

Rozlytrek (entrectinib) Capsules

Drug company: Genentech
866-422-2377

Rozlytrek is a kinase inhibitor used for the treatment of patients age 12 or older with solid tumors that are associated with a neurotrophic tyrosine receptor kinase (NTRK) gene fusion, are metastatic or are not candidates for surgery, or have progressed after treatment or they have no alternative therapy.

Genentech Oncology offers 2 financial assistance programs for patients who have been prescribed Rozlytrek:

Genentech Oncology Co-pay Assistance Program

Patients who have private insurance will pay a $5 copay per prescription of Rozlytrek, with a benefit limit of $25,000 per year. Retroactive requests for assistance will be honored if the prescription was filled within 180 days before enrollment in this program.

Genentech Patient Foundation

This foundation provides Rozlytrek free of charge to uninsured or underinsured patients whose annual household income is less than $150,000 and who meet specific financial criteria. For households with more than 4 people, add $25,000 per each additional member. Rozlytrek is also provided free for patients who are unable to afford their out-of-pocket costs and cannot find other financial assistance.

Vitrakvi (larotrectinib) Capsules

Drug company: Bayer
844-634-8725

Vitrakvi is a kinase inhibitor used for the treatment of all patients with solid tumors that are associated with a neurotrophic tyrosine receptor kinase (NTRK) gene fusion and have no known acquired resistance mutation, are metastatic or are not candidates for surgery, or have no alternative treatments or have progressed after treatment.

Bayer offers 2 financial assistance programs for patients who have been prescribed Vitrakvi:

VITRAKVI $0 Co-pay Program

Through this program, patients who have commercial or private insurance may qualify for $0 copay for Vitrakvi, with a maximum program benefit of $25,000 per year. Patients enrolled in any type of government insurance or reimbursement programs are not eligible for this $0 Co-pay Program.

Bayer US Patient Assistance Foundation

This foundation provides Vitrakvi free of charge to patients who are uninsured or underinsured who meet specific financial criteria.

Table. Drugs Prescribed for Solid Tumors

  • Drug name (generic name)
  • Drug company
  • Indications
  • Patient support services
    Drug name (generic name)
  • Jemperli (dostarlimab-gxly) Injection
  • Drug company
  • GSK Oncology
  • Indications
  • Treatment of adults with solid tumors associated with dMMR, as determined by an FDA-approved test, that have progressed during or after treatment and who have no satisfactory alternative treatment options
  • Patient support services
  • Together with GSK Oncology Commercial Co-pay Program
    844-447-5662

    GSK Patient Assistance Program
    844-447-5662
    Drug name (generic name)
  • Keytruda (pembrolizumab)
  • Drug company
  • Merck
  • Indications
  • Treatment of adults and children with unresectable or metastatic, MSI-H or dMMR solid tumors that have progressed after previous treatment and who have no satisfactory alternative treatments
    Treatment of adults and children with unresectable or metastatic solid tumors and high tumor mutational burden, as determined by an FDA-approved test, that have progressed after previous treatment and who have no satisfactory alternative treatments
  • Patient support services
  • Merck Co-pay Assistance Program
    855-257-3932

    Merck Patient Assistance Program
    800-727-5400
    Drug name (generic name)
  • Rozlytrek (entrectinib) Capsules
  • Drug company
  • Genentech
  • Indications
  • Treatment of patients 12 or older with solid tumors and an NTRK gene fusion, are metastatic or are not candidates for surgery, or have progressed after treatment or they have no alternative therapy
  • Genentech Oncology Co-pay Assistance Program
  • Merck Co-pay Assistance Program
    855-692-6729

    Genentech Patient Foundation
    888-941-3331
    Drug name (generic name)
  • Vitrakvi (larotrectinib) Capsules
  • Drug company
  • Bayer
  • Indications
  • Treatment of all patients with solid tumors and an NTRK gene fusion, are metastatic or are not candidates for surgery, or have no alternative treatments or have progressed after treatment
  • Genentech Oncology Co-pay Assistance Program
  • VITRAKVI $0 Co-pay Program
    647-245-5637

    Bayer US Patient Assistance Foundation
    866-228-7723

dMMR indicates mismatch repair-deficient; MSI-H, microsatellite instability-high.


Share this:

Last modified: April 20, 2022

Report Broken Links

Have you encountered a problem with a URL (link) on this page not working or displaying an error message?

Help us fix it! Report broken links here.

Report Broken Link

Subscribe to CONQUER: the patient voice

Receive timely cancer news & updates, patient stories, and more.


Country
Race or Ethnicity
Gender
Profession or Role
Primary Interest
Other Interests